Recent advances in nanoscale materials for antibody-based cancer theranostics
Related Experiment Video
Updated: Nov 30, 2025
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
Deepak Kukkar1, Preeti Kukkar2, Vanish Kumar3
1Department of Nanotechnology, Sri Guru Granth Sahib World University, Fatehgarh Sahib, Punjab, 140406, India.
Abstract:
The quest for advanced management tools or options of various cancers has been on the rise to efficiently reduce their risks of mortality without the demerits of conventional treatments (e.g., undesirable side effects of the medications on non-target tissues, non-targeted distribution, slow clearance of the administered drugs, and the development of drug resistance over the duration of therapy). In this context, nanomaterials-antibody conjugates can offer numerous advantages in the development of cancer theranostics over conventional delivery systems (e.g., highly specific and enhanced biodistribution of the drug in targeted tissues, prolonged systemic circulation, low toxicity, and minimally invasive molecular imaging). This review comprehensively discusses and evaluates recent advances in the application of nanomaterial-antibody bioconjugates for cancer theranostics for the further advancement in the control of diverse cancerous diseases. Further, discussion is expanded to cover the various challenges and limitations associated with the design and development of nanomaterial-antibody conjugates applicable towards better management of cancer.
Insights
Nanomaterial-antibody conjugates offer advanced cancer theranostics, overcoming conventional treatment limitations like side effects and drug resistance. This review explores their potential for improved cancer management and molecular imaging.
Area of Science:
- Biomedical Engineering
- Oncology
- Nanotechnology
Background:
- Conventional cancer treatments face challenges including toxicity, poor drug distribution, and resistance.
- There is a growing need for advanced cancer management tools with improved efficacy and reduced side effects.
Purpose of the Study:
- To comprehensively review recent advances in nanomaterial-antibody bioconjugates for cancer theranostics.
- To evaluate the potential of these conjugates in improving cancer management and molecular imaging.
- To discuss the challenges and limitations in the development of nanomaterial-antibody conjugates.
Main Methods:
- Literature review of recent scientific publications on nanomaterial-antibody conjugates in cancer theranostics.
- Analysis of studies focusing on the advantages of nanomaterial-antibody conjugates over conventional therapies.
- Evaluation of challenges and limitations in the design and application of these bioconjugates.
Main Results:
- Nanomaterial-antibody conjugates demonstrate significant advantages, including enhanced specificity, improved biodistribution, prolonged circulation, and low toxicity.
- These conjugates enable minimally invasive molecular imaging alongside therapeutic delivery.
- Recent advances show promise for more effective control of diverse cancerous diseases.
Conclusions:
- Nanomaterial-antibody bioconjugates represent a promising frontier in cancer theranostics.
- Further research and development are crucial to overcome existing challenges and fully realize their therapeutic potential.
- These advanced systems offer a pathway to improved cancer management with reduced patient burden.
